Tredje AP fonden Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tredje AP fonden decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,728 shares of the company’s stock after selling 289 shares during the period. Tredje AP fonden’s holdings in Neurocrine Biosciences were worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Envestnet Portfolio Solutions Inc. lifted its holdings in Neurocrine Biosciences by 3.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock valued at $333,000 after purchasing an additional 78 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Neurocrine Biosciences by 0.6% in the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after buying an additional 84 shares in the last quarter. Balentine LLC boosted its holdings in Neurocrine Biosciences by 4.0% in the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock worth $305,000 after buying an additional 89 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after buying an additional 90 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in shares of Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after acquiring an additional 92 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In related news, insider Ingrid Delaet sold 273 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the sale, the insider now directly owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the sale, the director now owns 37,491 shares in the company, valued at $5,499,554.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,798 shares of company stock valued at $10,676,096. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $120.46 on Friday. The company has a 50-day moving average of $139.07 and a two-hundred day moving average of $138.24. The firm has a market cap of $12.12 billion, a PE ratio of 33.18 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same quarter last year, the business posted $0.95 EPS. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Guggenheim increased their target price on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Robert W. Baird boosted their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating for the company in a report on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $162.20.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.